Payment overview · 2025
General Payments
$308.73
13 reported records · 9 companies
Healthcare provider profile · identity verified
Michelle Boone, DNP, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · NASHVILLE, AR · NPI 1215310784
Verified facts
What the public records show
CMS Open Payments records show Michelle Boone, DNP, APRN received $308.73 in general payments during 2025 across 13 reported records.
Corcept Therapeutics accounted for 36.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trintellix by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $111.09 | 36.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $59.91 | 19.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.56 | 10.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $29.25 | 9.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.87 | 5.1% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.63 | 5.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $15.44 | 5.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.31 | 4.6% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $13.67 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $308.73 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $111.09 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $59.91 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.56 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $29.25 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Duloxetine Hcl | Duloxetine Hcl | 173 | 23 |
| Atorvastatin Calcium | Atorvastatin Calcium | 170 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 140 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 127 | 27 |
| Lisinopril | Lisinopril | 127 | 24 |
| Alprazolam | Alprazolam | 118 | 19 |
| Buspirone Hcl | Buspirone Hcl | 116 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 24 |
| Gabapentin | Gabapentin | 108 | 27 |
| Losartan Potassium | Losartan Potassium | 90 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 88 | 15 |
| Metformin Hcl | Metformin Hcl | 83 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 82 | 20 |
| Omeprazole | Omeprazole | 80 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 13 |
| Potassium Chloride | Potassium Chloride | 71 | 16 |
| Furosemide | Furosemide | 69 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 15 |
| Pregabalin | Pregabalin | 60 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 15 |
| Meloxicam | Meloxicam | 54 | 15 |
| Glipizide Er | Glipizide | 52 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 52 | 13 |
| Mounjaro | Tirzepatide | 51 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 49 | suppressed |
| Clonazepam | Clonazepam | 48 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | suppressed |
| Atenolol | Atenolol | 44 | suppressed |
| Prednisone | Prednisone | 44 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 11 |
| Divalproex Sodium | Divalproex Sodium | 38 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 38 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 38 | 15 |
| Estradiol | Estradiol | 37 | suppressed |
| Mirtazapine | Mirtazapine | 37 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 35 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 35 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 33 | suppressed |
| Carvedilol | Carvedilol | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Metolazone | Metolazone | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Simvastatin | Simvastatin | 25 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Pentoxifylline | Pentoxifylline | 21 | suppressed |
| Progesterone | Progesterone, Micronized | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 13 |
| Allopurinol | Allopurinol | 19 | suppressed |
| Azithromycin | Azithromycin | 19 | 15 |
| Ozempic | Semaglutide | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Buprenorphine | Buprenorphine | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Jardiance | Empagliflozin | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Oxazepam | Oxazepam | 12 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Austedo | Deutetrabenazine | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Tacrolimus | Tacrolimus | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $308.73 · 13 records | Corcept Therapeutics | AUSTEDO XR, Auvelity, CAPLYTA, FANAPT, HETLIOZ, Korlym, QUTENZA, REXULTI, TRINTELLIX, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error